OncoCyte Corporation (OCX)
- Previous Close
2.6900 - Open
2.6200 - Bid --
- Ask --
- Day's Range
2.6200 - 2.7000 - 52 Week Range
2.0800 - 4.8600 - Volume
7,543 - Avg. Volume
63,474 - Market Cap (intraday)
36.084M - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-5.3200 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.06
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
www.oncocyte.com43
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: OCX
Performance Overview: OCX
Trailing total returns as of 6/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCX
Valuation Measures
Market Cap
35.42M
Enterprise Value
33.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.77
Price/Book (mrq)
3.06
Enterprise Value/Revenue
24.00
Enterprise Value/EBITDA
-1.25
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.75%
Return on Equity (ttm)
-132.29%
Revenue (ttm)
1.38M
Net Income Avi to Common (ttm)
-40.03M
Diluted EPS (ttm)
-5.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.58M
Total Debt/Equity (mrq)
19.71%
Levered Free Cash Flow (ttm)
-5.05M
Research Analysis: OCX
Company Insights: OCX
OCX does not have Company Insights
Research Reports: OCX
Daily – Vickers Top Insider Picks for 09/27/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/26/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/23/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/22/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.